OnKure Therapeutics (NASDAQ:OKUR) Given New $30.00 Price Target at Oppenheimer

OnKure Therapeutics (NASDAQ:OKUR) had its price target reduced by Oppenheimer from $35.00 to $30.00 in a research report report published on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities analysts also recently commented on OKUR. Leerink Partners started coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective for the company. Leerink Partnrs raised OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, OnKure Therapeutics has a consensus rating of “Buy” and a consensus price target of $34.33.

OnKure Therapeutics Stock Performance

NASDAQ OKUR opened at $4.95 on Tuesday. The firm has a market cap of $16.55 million, a P/E ratio of -0.41 and a beta of 0.28. The firm has a 50-day moving average price of $5.97. OnKure Therapeutics has a 1-year low of $4.57 and a 1-year high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last released its earnings results on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51). On average, sell-side analysts anticipate that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Hedge Funds Weigh In On OnKure Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC acquired a new position in OnKure Therapeutics in the fourth quarter valued at approximately $75,000. OMERS ADMINISTRATION Corp acquired a new position in OnKure Therapeutics in the fourth quarter valued at approximately $104,000. Walleye Capital LLC acquired a new position in OnKure Therapeutics in the fourth quarter valued at approximately $116,000. Two Sigma Advisers LP acquired a new position in OnKure Therapeutics in the fourth quarter valued at approximately $122,000. Finally, Shay Capital LLC acquired a new position in OnKure Therapeutics in the fourth quarter valued at approximately $129,000. 90.98% of the stock is owned by institutional investors and hedge funds.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.